Moreover, efficacy of programmed cell death 1/programmed death ligand 1(PD1/PD-L1) inhibitors has been reported in preclinical glioma models and in individual human cases (Reardon et al., 2016; Berghoff et al., 2017; Kim et al., 2017). The gene discussed is PDCD1; the disease is glioma.